Clinical Trial

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

Study acronym: PANSOTO
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2026-04-24
Trial Details
NCT Number NCT06892054
Lead Sponsor Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborators: Apices Soluciones S.L., GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions Pancreatic Adenocarcinoma
Enrollment 15 participants
Start Date 2025-08-08
Primary Completion 2030-08-08 (estimated)
Study Completion 2030-08-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-30